When and how to use antidotes for the reversal of direct oral anticoagulants: guidance from the SSC of the ISTH | Zendy

Levy J. H. | Zendy; Ageno W. | Zendy; Chan N. C. | Zendy; Crowther M. | Zendy; Verhamme P. | Zendy; Weitz J. I. | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

When and how to use antidotes for the reversal of direct oral anticoagulants: guidance from the SSC of the ISTH

Author(s) -

Levy J. H.,

Ageno W.,

Chan N. C.,

Crowther M.,

Verhamme P.,

Weitz J. I.

Publication year - 2016

Publication title -

journal of thrombosis and haemostasis

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.947

H-Index - 178

eISSN - 1538-7836

pISSN - 1538-7933

DOI - 10.1111/jth.13227

Subject(s) - apixaban , edoxaban , rivaroxaban , dabigatran , medicine , atrial fibrillation , vitamin k , stroke (engine) , intracranial bleeding , intensive care medicine , warfarin , mechanical engineering , engineering

J . H . LEVY ,* W. AGENO,† N. C . CHAN,‡ M. CROWTHER ,§ P . VERHAMME ¶ and J . I . WE ITZ ,§ FOR THE SUBCOMMITTEE ON CONTROL OF ANT ICOAGULAT ION *Duke University School of Medicine, Durham, NC, USA; †University of Insubria, Varese, Italy; ‡Monash University, Clayton, Vic., Australia; §McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON, Canada; and ¶University of Leuven, Leuven, Belgium

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research